Besides, nilotinib led to higher rates of BCR-ABL1IS ≤10% and BCR-ABL1IS ≤1% at 3 months than imatinib.(Saglio et al. 2010) ENEST1st was a phase 3b, multicenter, single-arm open-label study evaluating the efficacy and safety of nilotinib in a large population of patients with newly diagnosed Ph+ CML-CP, with an emphasis on deep molecular response. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.